Get Involved in Our Research Projects
Carstensen M.S., et al. "40 Hz invisible spectral flicker and its potential use in Alzheimer's light therapy treatment" Proc. SPIE 11221, Mechanisms of Photobiomodulation Therapy XV, (11 March 2020)Read more
Zibrandtsen IC, Agger M, Kjaer TW. "Gamma Entrainment in a Large Retrospective Cohort: Implications for Photic Stimulation Therapy for Alzheimer's Disease". J Alzheimers Dis. 2020;75(4):1181-1190.Read more
Carstensen M.S., et al. "Wavelength dependency of the critical flicker-fusion frequency: therapeutic 40 Hz light source in Alzheimer’s disease" Proc. SPIE 116280, Mechanisms and Techniques in Photodynamic Therapy and Photobiomodulation (5 March 2021)Read more
Amyloid beta (sometimes called beta-amyloid or β-amyloid or Aβ) is a neural peptide or amino acid that has been shown to aggregate or “clump” in Alzheimer’s Disease.
While it is not clear whether amyloid beta is the cause of the disease, a mechanism to combat it, or simply a result of it, there is a strong correlation between the severity of the disease and the amount of amyloid beta in the brain.
For this reason, a huge amount of resources have been spent on developing therapies designed to reduce the accumulation of amyloid beta in the brain. Some of these treatments are currently undergoing clinical trials, including gamma therapy.
The gamma brain frequency is often used in neuroscience and physiology to represent phenomena that occur approximately 40 times per second, or 40 Hertz (Hz).
It is not known why the gamma frequency activates cellular processes, but probably represents a complex phenomenon with both large-scale neuronal networks and subcellular interactions.
Importantly, in the mice study, frequencies outside the gamma range of 40 Hz have been shown not to have the same effect with regard to the clearance of amyloid beta.
Sign-up to our newsletter and receive new information about our developments, clinical trials and more.